Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 0+
Code: NCT00582621
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
for
Relapsed Refractory Multiple Myeloma (RRMM)
Location: Durham NC
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT05730036
Phase3, Recruiting
Umbilical Cord Blood Transplantation From Unrelated Donors
for
Acute Leukemia, Immune Deficiency Disorder,
Location: Rochester NY
Sponsor: University of Rochester
Sex: All
Age: 0 - 70+
Code: NCT03016806
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
for
Multiple Myeloma
Location: West Hollywood CA
Sponsor: Oncotherapeutics
Sex: All
Age: 18+
Code: NCT06209606
Early_phase1, Recruiting
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Location: Guilford CT, North Haven CT, New Haven CT, Derby CT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06465316
Phase1, Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
for
Relapsed or Refractory Multiple Myeloma,
Location: New York NY, Philadelphia PA, Charlotte NC, Houston TX,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05652335
Phase1, Recruiting
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
for
Monoclonal Gammopathy of Undetermined Significance (MGUS),
Location: Boston MA, Stony Brook NY, New York NY, Philadelphia PA,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06140524
Phase2, Recruiting
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
for
Multiple Myeloma
Location: Houston TX
Sponsor: The Methodist Hospital Research Institute
Sex: All
Age: 18+
Code: NCT06536413
Phase1, Phase2, Recruiting
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Boston MA, New York NY, Hackensack NJ, Buffalo NY,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06121843
Phase1, Recruiting
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: New York NY, Tampa FL, Columbus OH, Atlanta GA,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT03761108
Phase1, Phase2, Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
for
Relapsed or Refractory Multiple Myeloma (RRMM)
Location: Halifax, Boston MA, New York NY, Montreal,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company